Stories about Glucose

Subscribe to Glucose

11.12.2020 – 13:08

Roche Diabetes Care
Roche teams up with Diabeloop to advance the management of insulin pump therapy

Basel (ots/PRNewswire) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes1. - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management ...

more
11.12.2020 – 07:00

Roche Diabetes Care
Roche teams up with Diabeloop to advance the management of insulin pump therapy

Basel (ots) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management (iPDM). Roche ...

more
13.11.2020 – 08:00

ForaCare Suisse AG

FORA® 6 Blood Glucose Monitors Help Diabetic Patients Monitor COVID-19 Risks

more
10.08.2020 – 22:00

Ascensia Diabetes Care; PHC Holdings Corporation
PHC Holdings Corporation and Ascensia Diabetes Care Announce Financing Agreement and Exclusive Global Commercial Agreement With Senseonics

Tokyo and Basel, Switzerland (ots/PRNewswire) - PHC Holdings Corporation and Ascensia Diabetes Care, a PHC Group company, today announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose ...

more
15.06.2020 – 01:30

Novo Nordisk A/S
Investigational, Once-weekly Insulin Icodec Showed Comparable Efficacy and Safety to Once-daily Insulin Glargine U100 in Phase 2 Trial

Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US For journalistic assessment and preparation before publication. Today, Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the ...

more
13.06.2020 – 17:00

Novo Nordisk A/S
Switching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice

Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...

more
29.04.2020 – 10:51

Technische Universität München
Improving immunotherapy for cancer

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36023/ High resolution images: https://mediatum.ub.tum.de/1544218 NEWS RELEASE Cause for the lack of immune defense against tumors discovered Improving immunotherapy for cancer One of the reasons why cancer develops is because regulatory cells inhibit the body's ...

more
27.04.2020 – 17:22

Helmholtz Zentrum München

2
Beta cells from stem cells: Potential for cell replacement therapy

Read the study

more
02.04.2020 – 09:00

ForaCare Suisse AG

Autonomous Thermometer System Launched to Assist in COVID-19 Pandemic

more
18.12.2019 – 14:07

Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

more
04.12.2019 – 09:01

ForaCare Suisse AG
ForaCare Suisse AG Launches "Lab in the Pocket" Technology

ST. GALLEN, Switzerland (ots) - Innovative FORA 6 GTel Capability Provides 6 Tests with Single Device, SIM Direct-to-Telehealth Connectivity ForaCare Suisse AG announced the launch of its FORA 6 GTel multi-functional monitoring device with its new "Lab in the Pocket" technology (available on the GTel model and FORA 6 Series products). The innovative 6-in-1 monitoring technology provides seamless 3G/4G data transmission of ...

more
14.10.2019 – 17:27

Helmholtz Zentrum München

Discovery of potential novel therapeutic target for non-alcoholic fatty liver disease

Read the paper

more
19.09.2019 – 12:01

Novo Nordisk A/S
Tresiba® Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

Barcelona, Spain (ots/PRNewswire) - According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes ...

more
05.08.2019 – 13:12

Technische Universität München
Dry feed for superfood producers: study investigates nutritional behavior of insects

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10516 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35635/ High resolution pictures: https://mediatum.ub.tum.de/1516504 NEWS RELEASE International study investigates nutritional behavior of insects Dry feed ...

more
09.04.2019 – 10:04

Diabeloop; ViCentra
Diabeloop and ViCentra Announce European Distribution Partnership

Paris (ots/PRNewswire) - Diabeloop comprehensive and personalized system integrates Kaleido patch pump for autonomous type 1 diabetes management ViCentra, the company behind the Kaleido insulin pump, and Diabeloop are announcing that they are entering into a mutual distribution agreement for selected European countries. Following successful clinical studies using ViCentra's Kaleido micro insulin pump, Diabeloop's DBLG1 ...

more
29.03.2019 – 16:00

ForaCare Suisse AG
ForaCare Suisse AG Distributor, AlphaDiab, Ranked One of the Fastest Growing Companies in France

ST. GALLEN, Switzerland, (ots) - ForaCare Suisse AG (ForaCare, FORA) announced its distributor, AlphaDiab was recently named by Les Echos and Statista as one of the top fastest growing companies in France. With an average annual growth rate of 46 percent and an increase between 2014 and 2017 of 212 percent, ...

more
19.03.2019 – 23:47

Merck KGaA
Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...

more
30.01.2019 – 08:12

ForaCare Suisse AG

2
ForaCare Suisse AG forms service-oriented partnership with B. Braun

more
25.10.2018 – 13:34

Helmholtz Zentrum München
Two-pronged approach - Novel combined therapy tackles excess fatty tissue

A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for ...
Online Version

more
28.09.2018 – 10:01

Novo Nordisk A/S
International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...

more
11.09.2018 – 14:31

Merck KGaA
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...

more

1